nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—ESR2—uterine cancer	0.295	0.619	CbGaD
Fulvestrant—ESR1—uterine cancer	0.182	0.381	CbGaD
Fulvestrant—ESR1—Medroxyprogesterone Acetate—uterine cancer	0.172	0.531	CbGbCtD
Fulvestrant—ESR1—Progesterone—uterine cancer	0.114	0.352	CbGbCtD
Fulvestrant—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0177	0.0545	CbGbCtD
Fulvestrant—CYP3A4—Progesterone—uterine cancer	0.0117	0.0361	CbGbCtD
Fulvestrant—CYP3A4—Etoposide—uterine cancer	0.00525	0.0162	CbGbCtD
Fulvestrant—ESR2—oviduct—uterine cancer	0.00364	0.075	CbGeAlD
Fulvestrant—CYP3A4—Doxorubicin—uterine cancer	0.00358	0.011	CbGbCtD
Fulvestrant—ESR1—oviduct—uterine cancer	0.00249	0.0514	CbGeAlD
Fulvestrant—EPHX2—myometrium—uterine cancer	0.00222	0.0457	CbGeAlD
Fulvestrant—ESRRA—myometrium—uterine cancer	0.00194	0.04	CbGeAlD
Fulvestrant—NR1H4—renal system—uterine cancer	0.00185	0.038	CbGeAlD
Fulvestrant—ESRRA—uterine cervix—uterine cancer	0.00151	0.0311	CbGeAlD
Fulvestrant—EPHX2—mammalian vulva—uterine cancer	0.00151	0.0311	CbGeAlD
Fulvestrant—NR1H4—female reproductive system—uterine cancer	0.00148	0.0305	CbGeAlD
Fulvestrant—ESRRA—decidua—uterine cancer	0.00144	0.0297	CbGeAlD
Fulvestrant—EPHX2—uterus—uterine cancer	0.00144	0.0296	CbGeAlD
Fulvestrant—ESRRA—renal system—uterine cancer	0.00141	0.0291	CbGeAlD
Fulvestrant—ESRRA—endometrium—uterine cancer	0.00137	0.0282	CbGeAlD
Fulvestrant—NR1H4—female gonad—uterine cancer	0.00135	0.0277	CbGeAlD
Fulvestrant—ESRRA—mammalian vulva—uterine cancer	0.00132	0.0272	CbGeAlD
Fulvestrant—ESRRA—uterus—uterine cancer	0.00126	0.0259	CbGeAlD
Fulvestrant—EPHX2—female gonad—uterine cancer	0.00118	0.0242	CbGeAlD
Fulvestrant—EPHX2—vagina—uterine cancer	0.00117	0.0241	CbGeAlD
Fulvestrant—ESRRA—female reproductive system—uterine cancer	0.00113	0.0233	CbGeAlD
Fulvestrant—ESRRA—female gonad—uterine cancer	0.00103	0.0212	CbGeAlD
Fulvestrant—ESRRA—vagina—uterine cancer	0.00102	0.0211	CbGeAlD
Fulvestrant—ESR2—epithelium—uterine cancer	0.000915	0.0188	CbGeAlD
Fulvestrant—ESR2—uterine cervix—uterine cancer	0.000907	0.0187	CbGeAlD
Fulvestrant—ESR2—smooth muscle tissue—uterine cancer	0.000881	0.0182	CbGeAlD
Fulvestrant—Estradiol—ESR2—uterine cancer	0.000879	0.619	CrCbGaD
Fulvestrant—NR1H4—lymph node—uterine cancer	0.000865	0.0178	CbGeAlD
Fulvestrant—ESR2—renal system—uterine cancer	0.000848	0.0175	CbGeAlD
Fulvestrant—ESR2—endometrium—uterine cancer	0.00082	0.0169	CbGeAlD
Fulvestrant—ESR1—myometrium—uterine cancer	0.000798	0.0164	CbGeAlD
Fulvestrant—EPHX2—lymph node—uterine cancer	0.000756	0.0156	CbGeAlD
Fulvestrant—ESR2—uterus—uterine cancer	0.000756	0.0156	CbGeAlD
Fulvestrant—ESR2—female reproductive system—uterine cancer	0.00068	0.014	CbGeAlD
Fulvestrant—ESRRA—lymph node—uterine cancer	0.000662	0.0136	CbGeAlD
Fulvestrant—ESR1—epithelium—uterine cancer	0.000626	0.0129	CbGeAlD
Fulvestrant—ESR1—uterine cervix—uterine cancer	0.000621	0.0128	CbGeAlD
Fulvestrant—ESR2—female gonad—uterine cancer	0.000618	0.0127	CbGeAlD
Fulvestrant—ESR2—vagina—uterine cancer	0.000615	0.0127	CbGeAlD
Fulvestrant—ESR1—smooth muscle tissue—uterine cancer	0.000604	0.0124	CbGeAlD
Fulvestrant—ESR1—decidua—uterine cancer	0.000592	0.0122	CbGeAlD
Fulvestrant—ESR1—renal system—uterine cancer	0.000581	0.012	CbGeAlD
Fulvestrant—ESR1—endometrium—uterine cancer	0.000562	0.0116	CbGeAlD
Fulvestrant—Estradiol—ESR1—uterine cancer	0.000542	0.381	CrCbGaD
Fulvestrant—ESR1—uterus—uterine cancer	0.000518	0.0107	CbGeAlD
Fulvestrant—ESR1—female reproductive system—uterine cancer	0.000465	0.00959	CbGeAlD
Fulvestrant—ESR1—female gonad—uterine cancer	0.000423	0.00872	CbGeAlD
Fulvestrant—ESR1—vagina—uterine cancer	0.000421	0.00867	CbGeAlD
Fulvestrant—ESR2—lymph node—uterine cancer	0.000398	0.00819	CbGeAlD
Fulvestrant—CYP3A4—renal system—uterine cancer	0.000324	0.00668	CbGeAlD
Fulvestrant—ESR1—lymph node—uterine cancer	0.000272	0.00561	CbGeAlD
Fulvestrant—CYP3A4—female reproductive system—uterine cancer	0.00026	0.00535	CbGeAlD
Fulvestrant—Skin disorder—Progesterone—uterine cancer	0.000249	0.00281	CcSEcCtD
Fulvestrant—Hyperhidrosis—Progesterone—uterine cancer	0.000248	0.0028	CcSEcCtD
Fulvestrant—Anorexia—Progesterone—uterine cancer	0.000244	0.00276	CcSEcCtD
Fulvestrant—Myalgia—Medroxyprogesterone Acetate—uterine cancer	0.000242	0.00274	CcSEcCtD
Fulvestrant—Chest pain—Medroxyprogesterone Acetate—uterine cancer	0.000242	0.00274	CcSEcCtD
Fulvestrant—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	0.000242	0.00274	CcSEcCtD
Fulvestrant—Anxiety—Medroxyprogesterone Acetate—uterine cancer	0.000241	0.00273	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.00024	0.00272	CcSEcCtD
Fulvestrant—Vasodilation procedure—Epirubicin—uterine cancer	0.000234	0.00265	CcSEcCtD
Fulvestrant—Vasodilation—Epirubicin—uterine cancer	0.000234	0.00265	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Progesterone—uterine cancer	0.000233	0.00264	CcSEcCtD
Fulvestrant—Injection site pain—Doxorubicin—uterine cancer	0.000233	0.00264	CcSEcCtD
Fulvestrant—Insomnia—Progesterone—uterine cancer	0.000232	0.00262	CcSEcCtD
Fulvestrant—Infection—Medroxyprogesterone Acetate—uterine cancer	0.000231	0.0026	CcSEcCtD
Fulvestrant—Paraesthesia—Progesterone—uterine cancer	0.00023	0.0026	CcSEcCtD
Fulvestrant—Dyspnoea—Progesterone—uterine cancer	0.000228	0.00258	CcSEcCtD
Fulvestrant—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000228	0.00257	CcSEcCtD
Fulvestrant—Dyspepsia—Progesterone—uterine cancer	0.000225	0.00255	CcSEcCtD
Fulvestrant—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000225	0.00255	CcSEcCtD
Fulvestrant—Cough increased—Epirubicin—uterine cancer	0.000225	0.00254	CcSEcCtD
Fulvestrant—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.000224	0.00253	CcSEcCtD
Fulvestrant—Decreased appetite—Progesterone—uterine cancer	0.000223	0.00252	CcSEcCtD
Fulvestrant—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.000221	0.0025	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Progesterone—uterine cancer	0.000221	0.0025	CcSEcCtD
Fulvestrant—Fatigue—Progesterone—uterine cancer	0.000221	0.00249	CcSEcCtD
Fulvestrant—Pain—Progesterone—uterine cancer	0.000219	0.00247	CcSEcCtD
Fulvestrant—Constipation—Progesterone—uterine cancer	0.000219	0.00247	CcSEcCtD
Fulvestrant—Blood bilirubin increased—Epirubicin—uterine cancer	0.000218	0.00246	CcSEcCtD
Fulvestrant—Vasodilation procedure—Doxorubicin—uterine cancer	0.000217	0.00245	CcSEcCtD
Fulvestrant—Vasodilation—Doxorubicin—uterine cancer	0.000217	0.00245	CcSEcCtD
Fulvestrant—Bone pain—Epirubicin—uterine cancer	0.000215	0.00243	CcSEcCtD
Fulvestrant—Inflammation—Epirubicin—uterine cancer	0.000212	0.0024	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.000211	0.00239	CcSEcCtD
Fulvestrant—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.00021	0.00237	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Progesterone—uterine cancer	0.000209	0.00237	CcSEcCtD
Fulvestrant—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.000208	0.00235	CcSEcCtD
Fulvestrant—Musculoskeletal pain—Epirubicin—uterine cancer	0.000208	0.00235	CcSEcCtD
Fulvestrant—Cough increased—Doxorubicin—uterine cancer	0.000208	0.00235	CcSEcCtD
Fulvestrant—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000207	0.00234	CcSEcCtD
Fulvestrant—Infestation NOS—Etoposide—uterine cancer	0.000205	0.00232	CcSEcCtD
Fulvestrant—Infestation—Etoposide—uterine cancer	0.000205	0.00232	CcSEcCtD
Fulvestrant—Anaemia—Dactinomycin—uterine cancer	0.000205	0.00232	CcSEcCtD
Fulvestrant—Injection site reaction—Epirubicin—uterine cancer	0.000205	0.00231	CcSEcCtD
Fulvestrant—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000204	0.00231	CcSEcCtD
Fulvestrant—Urticaria—Progesterone—uterine cancer	0.000204	0.0023	CcSEcCtD
Fulvestrant—Body temperature increased—Progesterone—uterine cancer	0.000203	0.00229	CcSEcCtD
Fulvestrant—Abdominal pain—Progesterone—uterine cancer	0.000203	0.00229	CcSEcCtD
Fulvestrant—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000202	0.00228	CcSEcCtD
Fulvestrant—Blood bilirubin increased—Doxorubicin—uterine cancer	0.000201	0.00227	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.0002	0.00226	CcSEcCtD
Fulvestrant—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.0002	0.00226	CcSEcCtD
Fulvestrant—Bone pain—Doxorubicin—uterine cancer	0.000199	0.00225	CcSEcCtD
Fulvestrant—Leukopenia—Dactinomycin—uterine cancer	0.000199	0.00224	CcSEcCtD
Fulvestrant—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000198	0.00224	CcSEcCtD
Fulvestrant—Inflammation—Doxorubicin—uterine cancer	0.000196	0.00222	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Etoposide—uterine cancer	0.000194	0.00219	CcSEcCtD
Fulvestrant—Musculoskeletal pain—Doxorubicin—uterine cancer	0.000193	0.00218	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00019	0.00214	CcSEcCtD
Fulvestrant—Injection site reaction—Doxorubicin—uterine cancer	0.000189	0.00214	CcSEcCtD
Fulvestrant—Myalgia—Dactinomycin—uterine cancer	0.000189	0.00213	CcSEcCtD
Fulvestrant—Hypersensitivity—Progesterone—uterine cancer	0.000189	0.00213	CcSEcCtD
Fulvestrant—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000184	0.00208	CcSEcCtD
Fulvestrant—Asthenia—Progesterone—uterine cancer	0.000184	0.00208	CcSEcCtD
Fulvestrant—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000183	0.00207	CcSEcCtD
Fulvestrant—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000183	0.00207	CcSEcCtD
Fulvestrant—Pruritus—Progesterone—uterine cancer	0.000181	0.00205	CcSEcCtD
Fulvestrant—Infection—Dactinomycin—uterine cancer	0.00018	0.00203	CcSEcCtD
Fulvestrant—Diarrhoea—Progesterone—uterine cancer	0.000175	0.00198	CcSEcCtD
Fulvestrant—Anorexia—Dactinomycin—uterine cancer	0.000173	0.00195	CcSEcCtD
Fulvestrant—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000171	0.00193	CcSEcCtD
Fulvestrant—Dizziness—Progesterone—uterine cancer	0.000169	0.00191	CcSEcCtD
Fulvestrant—Angiopathy—Etoposide—uterine cancer	0.000167	0.00189	CcSEcCtD
Fulvestrant—Immune system disorder—Etoposide—uterine cancer	0.000167	0.00188	CcSEcCtD
Fulvestrant—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000167	0.00188	CcSEcCtD
Fulvestrant—Hepatic failure—Epirubicin—uterine cancer	0.000166	0.00188	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000165	0.00186	CcSEcCtD
Fulvestrant—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000164	0.00185	CcSEcCtD
Fulvestrant—Vomiting—Progesterone—uterine cancer	0.000163	0.00184	CcSEcCtD
Fulvestrant—Rash—Progesterone—uterine cancer	0.000162	0.00182	CcSEcCtD
Fulvestrant—Dermatitis—Progesterone—uterine cancer	0.000161	0.00182	CcSEcCtD
Fulvestrant—Headache—Progesterone—uterine cancer	0.00016	0.00181	CcSEcCtD
Fulvestrant—Hot flush—Epirubicin—uterine cancer	0.00016	0.0018	CcSEcCtD
Fulvestrant—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000159	0.00179	CcSEcCtD
Fulvestrant—Menopausal symptoms—Epirubicin—uterine cancer	0.000158	0.00179	CcSEcCtD
Fulvestrant—Decreased appetite—Dactinomycin—uterine cancer	0.000157	0.00178	CcSEcCtD
Fulvestrant—Fatigue—Dactinomycin—uterine cancer	0.000156	0.00176	CcSEcCtD
Fulvestrant—Back pain—Etoposide—uterine cancer	0.000155	0.00175	CcSEcCtD
Fulvestrant—Pain—Dactinomycin—uterine cancer	0.000155	0.00175	CcSEcCtD
Fulvestrant—Hepatic failure—Doxorubicin—uterine cancer	0.000154	0.00174	CcSEcCtD
Fulvestrant—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000153	0.00173	CcSEcCtD
Fulvestrant—Nausea—Progesterone—uterine cancer	0.000152	0.00172	CcSEcCtD
Fulvestrant—Pain in extremity—Epirubicin—uterine cancer	0.000149	0.00169	CcSEcCtD
Fulvestrant—Anaemia—Etoposide—uterine cancer	0.000148	0.00168	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000148	0.00167	CcSEcCtD
Fulvestrant—Hot flush—Doxorubicin—uterine cancer	0.000148	0.00167	CcSEcCtD
Fulvestrant—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000148	0.00167	CcSEcCtD
Fulvestrant—Menopausal symptoms—Doxorubicin—uterine cancer	0.000147	0.00166	CcSEcCtD
Fulvestrant—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000146	0.00165	CcSEcCtD
Fulvestrant—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000146	0.00165	CcSEcCtD
Fulvestrant—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000145	0.00164	CcSEcCtD
Fulvestrant—Vertigo—Etoposide—uterine cancer	0.000144	0.00163	CcSEcCtD
Fulvestrant—Leukopenia—Etoposide—uterine cancer	0.000144	0.00162	CcSEcCtD
Fulvestrant—Body temperature increased—Dactinomycin—uterine cancer	0.000143	0.00162	CcSEcCtD
Fulvestrant—Abdominal pain—Dactinomycin—uterine cancer	0.000143	0.00162	CcSEcCtD
Fulvestrant—Cough—Etoposide—uterine cancer	0.00014	0.00158	CcSEcCtD
Fulvestrant—Pain in extremity—Doxorubicin—uterine cancer	0.000138	0.00156	CcSEcCtD
Fulvestrant—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000138	0.00156	CcSEcCtD
Fulvestrant—Chest pain—Etoposide—uterine cancer	0.000137	0.00154	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000136	0.00153	CcSEcCtD
Fulvestrant—Breast disorder—Epirubicin—uterine cancer	0.000135	0.00153	CcSEcCtD
Fulvestrant—Hypersensitivity—Dactinomycin—uterine cancer	0.000133	0.00151	CcSEcCtD
Fulvestrant—Infection—Etoposide—uterine cancer	0.00013	0.00147	CcSEcCtD
Fulvestrant—Asthenia—Dactinomycin—uterine cancer	0.00013	0.00147	CcSEcCtD
Fulvestrant—Influenza—Epirubicin—uterine cancer	0.000129	0.00146	CcSEcCtD
Fulvestrant—Skin disorder—Etoposide—uterine cancer	0.000127	0.00144	CcSEcCtD
Fulvestrant—Hyperhidrosis—Etoposide—uterine cancer	0.000127	0.00143	CcSEcCtD
Fulvestrant—Breast disorder—Doxorubicin—uterine cancer	0.000125	0.00141	CcSEcCtD
Fulvestrant—Anorexia—Etoposide—uterine cancer	0.000125	0.00141	CcSEcCtD
Fulvestrant—Diarrhoea—Dactinomycin—uterine cancer	0.000124	0.0014	CcSEcCtD
Fulvestrant—Influenza—Doxorubicin—uterine cancer	0.00012	0.00135	CcSEcCtD
Fulvestrant—Paraesthesia—Etoposide—uterine cancer	0.000118	0.00133	CcSEcCtD
Fulvestrant—Dyspnoea—Etoposide—uterine cancer	0.000117	0.00132	CcSEcCtD
Fulvestrant—Infestation NOS—Epirubicin—uterine cancer	0.000115	0.0013	CcSEcCtD
Fulvestrant—Infestation—Epirubicin—uterine cancer	0.000115	0.0013	CcSEcCtD
Fulvestrant—Vomiting—Dactinomycin—uterine cancer	0.000115	0.0013	CcSEcCtD
Fulvestrant—Rash—Dactinomycin—uterine cancer	0.000114	0.00129	CcSEcCtD
Fulvestrant—Decreased appetite—Etoposide—uterine cancer	0.000114	0.00129	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Etoposide—uterine cancer	0.000113	0.00128	CcSEcCtD
Fulvestrant—Fatigue—Etoposide—uterine cancer	0.000113	0.00128	CcSEcCtD
Fulvestrant—Pain—Etoposide—uterine cancer	0.000112	0.00127	CcSEcCtD
Fulvestrant—Constipation—Etoposide—uterine cancer	0.000112	0.00127	CcSEcCtD
Fulvestrant—Urinary tract infection—Epirubicin—uterine cancer	0.000112	0.00126	CcSEcCtD
Fulvestrant—Sweating—Epirubicin—uterine cancer	0.00011	0.00125	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Epirubicin—uterine cancer	0.000109	0.00123	CcSEcCtD
Fulvestrant—Nausea—Dactinomycin—uterine cancer	0.000108	0.00121	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Etoposide—uterine cancer	0.000107	0.00121	CcSEcCtD
Fulvestrant—Infestation NOS—Doxorubicin—uterine cancer	0.000107	0.0012	CcSEcCtD
Fulvestrant—Infestation—Doxorubicin—uterine cancer	0.000107	0.0012	CcSEcCtD
Fulvestrant—NR1H4—PPARA activates gene expression—EP300—uterine cancer	0.000105	0.00175	CbGpPWpGaD
Fulvestrant—Urticaria—Etoposide—uterine cancer	0.000104	0.00118	CcSEcCtD
Fulvestrant—Haemoglobin—Epirubicin—uterine cancer	0.000104	0.00117	CcSEcCtD
Fulvestrant—Body temperature increased—Etoposide—uterine cancer	0.000104	0.00117	CcSEcCtD
Fulvestrant—Abdominal pain—Etoposide—uterine cancer	0.000104	0.00117	CcSEcCtD
Fulvestrant—Urinary tract infection—Doxorubicin—uterine cancer	0.000104	0.00117	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—CDKN2B—uterine cancer	0.000103	0.00172	CbGpPWpGaD
Fulvestrant—Haemorrhage—Epirubicin—uterine cancer	0.000103	0.00117	CcSEcCtD
Fulvestrant—Hepatitis—Epirubicin—uterine cancer	0.000103	0.00117	CcSEcCtD
Fulvestrant—NR1H4—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—uterine cancer	0.000103	0.00171	CbGpPWpGaD
Fulvestrant—Pharyngitis—Epirubicin—uterine cancer	0.000103	0.00116	CcSEcCtD
Fulvestrant—Sweating—Doxorubicin—uterine cancer	0.000102	0.00115	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—SUZ12—uterine cancer	0.000102	0.00169	CbGpPWpGaD
Fulvestrant—Oedema peripheral—Epirubicin—uterine cancer	0.000102	0.00115	CcSEcCtD
Fulvestrant—Connective tissue disorder—Epirubicin—uterine cancer	0.000102	0.00115	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000101	0.00114	CcSEcCtD
Fulvestrant—ESR1—FOXM1 transcription factor network—EP300—uterine cancer	9.99e-05	0.00166	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—NDUFB11—uterine cancer	9.92e-05	0.00165	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—SRD5A2—uterine cancer	9.92e-05	0.00165	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	9.88e-05	0.00164	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—STAR—uterine cancer	9.82e-05	0.00163	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—AKR1B1—uterine cancer	9.82e-05	0.00163	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—CCL2—uterine cancer	9.79e-05	0.00162	CbGpPWpGaD
Fulvestrant—ESR1—Estrogen signaling pathway—AKT1—uterine cancer	9.77e-05	0.00162	CbGpPWpGaD
Fulvestrant—ESRRA—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—uterine cancer	9.71e-05	0.00161	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	9.7e-05	0.00161	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Etoposide—uterine cancer	9.65e-05	0.00109	CcSEcCtD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	9.64e-05	0.0016	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—POLD1—uterine cancer	9.64e-05	0.0016	CbGpPWpGaD
Fulvestrant—ESR1—FOXA1 transcription factor network—EP300—uterine cancer	9.62e-05	0.0016	CbGpPWpGaD
Fulvestrant—Haemoglobin—Doxorubicin—uterine cancer	9.62e-05	0.00109	CcSEcCtD
Fulvestrant—Haemorrhage—Doxorubicin—uterine cancer	9.57e-05	0.00108	CcSEcCtD
Fulvestrant—Hepatitis—Doxorubicin—uterine cancer	9.57e-05	0.00108	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—NRAS—uterine cancer	9.52e-05	0.00158	CbGpPWpGaD
Fulvestrant—Pharyngitis—Doxorubicin—uterine cancer	9.49e-05	0.00107	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—SMAD3—uterine cancer	9.45e-05	0.00157	CbGpPWpGaD
Fulvestrant—Oedema peripheral—Doxorubicin—uterine cancer	9.42e-05	0.00106	CcSEcCtD
Fulvestrant—Asthenia—Etoposide—uterine cancer	9.4e-05	0.00106	CcSEcCtD
Fulvestrant—Connective tissue disorder—Doxorubicin—uterine cancer	9.4e-05	0.00106	CcSEcCtD
Fulvestrant—Angiopathy—Epirubicin—uterine cancer	9.38e-05	0.00106	CcSEcCtD
Fulvestrant—Immune system disorder—Epirubicin—uterine cancer	9.34e-05	0.00105	CcSEcCtD
Fulvestrant—NR1H4—Generic Transcription Pathway—ESR2—uterine cancer	9.29e-05	0.00154	CbGpPWpGaD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—EP300—uterine cancer	9.29e-05	0.00154	CbGpPWpGaD
Fulvestrant—Pruritus—Etoposide—uterine cancer	9.27e-05	0.00105	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—PGR—uterine cancer	9.19e-05	0.00153	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	9.1e-05	0.00151	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—AKR1C1—uterine cancer	9.01e-05	0.0015	CbGpPWpGaD
Fulvestrant—Malnutrition—Epirubicin—uterine cancer	9e-05	0.00102	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CYP19A1—uterine cancer	9e-05	0.00149	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—STK11—uterine cancer	9e-05	0.00149	CbGpPWpGaD
Fulvestrant—Diarrhoea—Etoposide—uterine cancer	8.97e-05	0.00101	CcSEcCtD
Fulvestrant—ESR2—Gene Expression—SUZ12—uterine cancer	8.88e-05	0.00147	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—CXCL8—uterine cancer	8.87e-05	0.00147	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	8.86e-05	0.00147	CbGpPWpGaD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	8.79e-05	0.00146	CbGpPWpGaD
Fulvestrant—Back pain—Epirubicin—uterine cancer	8.71e-05	0.000983	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	8.69e-05	0.00144	CbGpPWpGaD
Fulvestrant—Angiopathy—Doxorubicin—uterine cancer	8.68e-05	0.00098	CcSEcCtD
Fulvestrant—Dizziness—Etoposide—uterine cancer	8.67e-05	0.000979	CcSEcCtD
Fulvestrant—Immune system disorder—Doxorubicin—uterine cancer	8.64e-05	0.000976	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—CDKN2A—uterine cancer	8.53e-05	0.00142	CbGpPWpGaD
Fulvestrant—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	8.34e-05	0.00139	CbGpPWpGaD
Fulvestrant—Vomiting—Etoposide—uterine cancer	8.33e-05	0.000941	CcSEcCtD
Fulvestrant—Malnutrition—Doxorubicin—uterine cancer	8.33e-05	0.000941	CcSEcCtD
Fulvestrant—Anaemia—Epirubicin—uterine cancer	8.32e-05	0.00094	CcSEcCtD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—uterine cancer	8.27e-05	0.00137	CbGpPWpGaD
Fulvestrant—Rash—Etoposide—uterine cancer	8.26e-05	0.000933	CcSEcCtD
Fulvestrant—Dermatitis—Etoposide—uterine cancer	8.25e-05	0.000932	CcSEcCtD
Fulvestrant—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	8.23e-05	0.00137	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	8.21e-05	0.00136	CbGpPWpGaD
Fulvestrant—Headache—Etoposide—uterine cancer	8.21e-05	0.000927	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—KRAS—uterine cancer	8.2e-05	0.00136	CbGpPWpGaD
Fulvestrant—Vertigo—Epirubicin—uterine cancer	8.09e-05	0.000913	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—CXCL8—uterine cancer	8.08e-05	0.00134	CbGpPWpGaD
Fulvestrant—Leukopenia—Epirubicin—uterine cancer	8.06e-05	0.00091	CcSEcCtD
Fulvestrant—Back pain—Doxorubicin—uterine cancer	8.06e-05	0.00091	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—RRM2—uterine cancer	8.03e-05	0.00133	CbGpPWpGaD
Fulvestrant—Cough—Epirubicin—uterine cancer	7.85e-05	0.000887	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—DCN—uterine cancer	7.8e-05	0.00129	CbGpPWpGaD
Fulvestrant—Nausea—Etoposide—uterine cancer	7.78e-05	0.000879	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—CXCL8—uterine cancer	7.74e-05	0.00128	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—CDKN1B—uterine cancer	7.73e-05	0.00128	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—ERBB2—uterine cancer	7.72e-05	0.00128	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—ESR1—uterine cancer	7.71e-05	0.00128	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—POLD1—uterine cancer	7.7e-05	0.00128	CbGpPWpGaD
Fulvestrant—Anaemia—Doxorubicin—uterine cancer	7.7e-05	0.000869	CcSEcCtD
Fulvestrant—Myalgia—Epirubicin—uterine cancer	7.66e-05	0.000866	CcSEcCtD
Fulvestrant—Arthralgia—Epirubicin—uterine cancer	7.66e-05	0.000866	CcSEcCtD
Fulvestrant—Chest pain—Epirubicin—uterine cancer	7.66e-05	0.000866	CcSEcCtD
Fulvestrant—Anxiety—Epirubicin—uterine cancer	7.64e-05	0.000863	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	7.61e-05	0.00086	CcSEcCtD
Fulvestrant—ESR1—ATF-2 transcription factor network—EP300—uterine cancer	7.61e-05	0.00126	CbGpPWpGaD
Fulvestrant—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	7.59e-05	0.00126	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—CDKN2B—uterine cancer	7.56e-05	0.00126	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—CDKN1B—uterine cancer	7.56e-05	0.00125	CbGpPWpGaD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—PIK3CA—uterine cancer	7.53e-05	0.00125	CbGpPWpGaD
Fulvestrant—Vertigo—Doxorubicin—uterine cancer	7.48e-05	0.000845	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	7.48e-05	0.00124	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	7.46e-05	0.00124	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	7.46e-05	0.00124	CbGpPWpGaD
Fulvestrant—Leukopenia—Doxorubicin—uterine cancer	7.45e-05	0.000842	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—CYP11A1—uterine cancer	7.35e-05	0.00122	CbGpPWpGaD
Fulvestrant—Infection—Epirubicin—uterine cancer	7.3e-05	0.000824	CcSEcCtD
Fulvestrant—Cough—Doxorubicin—uterine cancer	7.27e-05	0.000821	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	7.25e-05	0.0012	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—AKR1C1—uterine cancer	7.21e-05	0.0012	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Epirubicin—uterine cancer	7.2e-05	0.000814	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—STAR—uterine cancer	7.17e-05	0.00119	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—AKR1B1—uterine cancer	7.17e-05	0.00119	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—CTNNB1—uterine cancer	7.14e-05	0.00119	CbGpPWpGaD
Fulvestrant—Skin disorder—Epirubicin—uterine cancer	7.13e-05	0.000806	CcSEcCtD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—EP300—uterine cancer	7.13e-05	0.00118	CbGpPWpGaD
Fulvestrant—Hyperhidrosis—Epirubicin—uterine cancer	7.1e-05	0.000802	CcSEcCtD
Fulvestrant—NR1H4—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—uterine cancer	7.1e-05	0.00118	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	7.09e-05	0.00118	CbGpPWpGaD
Fulvestrant—Chest pain—Doxorubicin—uterine cancer	7.09e-05	0.000801	CcSEcCtD
Fulvestrant—Myalgia—Doxorubicin—uterine cancer	7.09e-05	0.000801	CcSEcCtD
Fulvestrant—Arthralgia—Doxorubicin—uterine cancer	7.09e-05	0.000801	CcSEcCtD
Fulvestrant—Anxiety—Doxorubicin—uterine cancer	7.07e-05	0.000798	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	7.04e-05	0.000795	CcSEcCtD
Fulvestrant—ESR1—LKB1 signaling events—TP53—uterine cancer	7.01e-05	0.00116	CbGpPWpGaD
Fulvestrant—Anorexia—Epirubicin—uterine cancer	7e-05	0.000791	CcSEcCtD
Fulvestrant—ESR1—Signaling by ERBB4—FGFR2—uterine cancer	6.99e-05	0.00116	CbGpPWpGaD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—HRAS—uterine cancer	6.97e-05	0.00116	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—PTEN—uterine cancer	6.96e-05	0.00116	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—PGR—uterine cancer	6.95e-05	0.00115	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—AKR1C3—uterine cancer	6.94e-05	0.00115	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—EP300—uterine cancer	6.93e-05	0.00115	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—SMAD3—uterine cancer	6.9e-05	0.00115	CbGpPWpGaD
Fulvestrant—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	6.76e-05	0.00112	CbGpPWpGaD
Fulvestrant—Infection—Doxorubicin—uterine cancer	6.75e-05	0.000763	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	6.71e-05	0.00111	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Epirubicin—uterine cancer	6.69e-05	0.000756	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	6.68e-05	0.00111	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Doxorubicin—uterine cancer	6.67e-05	0.000753	CcSEcCtD
Fulvestrant—Insomnia—Epirubicin—uterine cancer	6.64e-05	0.00075	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—EP300—uterine cancer	6.64e-05	0.0011	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—EZH2—uterine cancer	6.6e-05	0.0011	CbGpPWpGaD
Fulvestrant—Skin disorder—Doxorubicin—uterine cancer	6.6e-05	0.000746	CcSEcCtD
Fulvestrant—Paraesthesia—Epirubicin—uterine cancer	6.6e-05	0.000745	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—CDKN2B—uterine cancer	6.59e-05	0.00109	CbGpPWpGaD
Fulvestrant—Hyperhidrosis—Doxorubicin—uterine cancer	6.57e-05	0.000742	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—VEGFA—uterine cancer	6.57e-05	0.00109	CbGpPWpGaD
Fulvestrant—Dyspnoea—Epirubicin—uterine cancer	6.55e-05	0.00074	CcSEcCtD
Fulvestrant—Anorexia—Doxorubicin—uterine cancer	6.48e-05	0.000732	CcSEcCtD
Fulvestrant—Dyspepsia—Epirubicin—uterine cancer	6.47e-05	0.00073	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—RRM2—uterine cancer	6.42e-05	0.00107	CbGpPWpGaD
Fulvestrant—Decreased appetite—Epirubicin—uterine cancer	6.39e-05	0.000721	CcSEcCtD
Fulvestrant—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	6.37e-05	0.00106	CbGpPWpGaD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	6.35e-05	0.00105	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	6.34e-05	0.00105	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Epirubicin—uterine cancer	6.34e-05	0.000716	CcSEcCtD
Fulvestrant—Fatigue—Epirubicin—uterine cancer	6.33e-05	0.000715	CcSEcCtD
Fulvestrant—ESR1—Gene Expression—PHF1—uterine cancer	6.29e-05	0.00104	CbGpPWpGaD
Fulvestrant—Pain—Epirubicin—uterine cancer	6.28e-05	0.00071	CcSEcCtD
Fulvestrant—Constipation—Epirubicin—uterine cancer	6.28e-05	0.00071	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—DCN—uterine cancer	6.23e-05	0.00104	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Doxorubicin—uterine cancer	6.19e-05	0.000699	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	6.18e-05	0.00103	CbGpPWpGaD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—AKT1—uterine cancer	6.15e-05	0.00102	CbGpPWpGaD
Fulvestrant—Insomnia—Doxorubicin—uterine cancer	6.15e-05	0.000694	CcSEcCtD
Fulvestrant—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	6.14e-05	0.00102	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—ESR2—uterine cancer	6.12e-05	0.00102	CbGpPWpGaD
Fulvestrant—Paraesthesia—Doxorubicin—uterine cancer	6.1e-05	0.000689	CcSEcCtD
Fulvestrant—Dyspnoea—Doxorubicin—uterine cancer	6.06e-05	0.000684	CcSEcCtD
Fulvestrant—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	6.06e-05	0.00101	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—SMAD3—uterine cancer	6.01e-05	0.000998	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Epirubicin—uterine cancer	6.01e-05	0.000678	CcSEcCtD
Fulvestrant—Dyspepsia—Doxorubicin—uterine cancer	5.98e-05	0.000676	CcSEcCtD
Fulvestrant—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	5.92e-05	0.000983	CbGpPWpGaD
Fulvestrant—Decreased appetite—Doxorubicin—uterine cancer	5.91e-05	0.000667	CcSEcCtD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—EP300—uterine cancer	5.9e-05	0.00098	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	5.9e-05	0.000979	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CYP11A1—uterine cancer	5.87e-05	0.000975	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Doxorubicin—uterine cancer	5.87e-05	0.000663	CcSEcCtD
Fulvestrant—Fatigue—Doxorubicin—uterine cancer	5.86e-05	0.000662	CcSEcCtD
Fulvestrant—Urticaria—Epirubicin—uterine cancer	5.84e-05	0.000659	CcSEcCtD
Fulvestrant—Constipation—Doxorubicin—uterine cancer	5.81e-05	0.000656	CcSEcCtD
Fulvestrant—Pain—Doxorubicin—uterine cancer	5.81e-05	0.000656	CcSEcCtD
Fulvestrant—Body temperature increased—Epirubicin—uterine cancer	5.81e-05	0.000656	CcSEcCtD
Fulvestrant—Abdominal pain—Epirubicin—uterine cancer	5.81e-05	0.000656	CcSEcCtD
Fulvestrant—NR1H4—Generic Transcription Pathway—ESR1—uterine cancer	5.63e-05	0.000935	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—POLD1—uterine cancer	5.63e-05	0.000935	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	5.58e-05	0.000927	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Doxorubicin—uterine cancer	5.56e-05	0.000628	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—AKR1C3—uterine cancer	5.55e-05	0.000921	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Epirubicin—uterine cancer	5.41e-05	0.000611	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—STK11—uterine cancer	5.41e-05	0.000897	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—CYP19A1—uterine cancer	5.41e-05	0.000897	CbGpPWpGaD
Fulvestrant—Urticaria—Doxorubicin—uterine cancer	5.4e-05	0.00061	CcSEcCtD
Fulvestrant—Abdominal pain—Doxorubicin—uterine cancer	5.37e-05	0.000607	CcSEcCtD
Fulvestrant—Body temperature increased—Doxorubicin—uterine cancer	5.37e-05	0.000607	CcSEcCtD
Fulvestrant—ESR1—Gene Expression—CHD4—uterine cancer	5.35e-05	0.000887	CbGpPWpGaD
Fulvestrant—Asthenia—Epirubicin—uterine cancer	5.27e-05	0.000595	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—AKR1C1—uterine cancer	5.27e-05	0.000874	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CDH1—uterine cancer	5.23e-05	0.000868	CbGpPWpGaD
Fulvestrant—Pruritus—Epirubicin—uterine cancer	5.2e-05	0.000587	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—PGR—uterine cancer	5.08e-05	0.000843	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.07e-05	0.000842	CbGpPWpGaD
Fulvestrant—Diarrhoea—Epirubicin—uterine cancer	5.03e-05	0.000568	CcSEcCtD
Fulvestrant—Hypersensitivity—Doxorubicin—uterine cancer	5.01e-05	0.000566	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—CDKN2B—uterine cancer	4.98e-05	0.000827	CbGpPWpGaD
Fulvestrant—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	4.98e-05	0.000826	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—ESR1—uterine cancer	4.91e-05	0.000815	CbGpPWpGaD
Fulvestrant—Asthenia—Doxorubicin—uterine cancer	4.88e-05	0.000551	CcSEcCtD
Fulvestrant—Dizziness—Epirubicin—uterine cancer	4.86e-05	0.000549	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.84e-05	0.000803	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—EZH2—uterine cancer	4.83e-05	0.000801	CbGpPWpGaD
Fulvestrant—Pruritus—Doxorubicin—uterine cancer	4.81e-05	0.000543	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—TP53—uterine cancer	4.75e-05	0.000788	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	4.75e-05	0.000788	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—RRM2—uterine cancer	4.69e-05	0.000779	CbGpPWpGaD
Fulvestrant—Vomiting—Epirubicin—uterine cancer	4.67e-05	0.000528	CcSEcCtD
Fulvestrant—Diarrhoea—Doxorubicin—uterine cancer	4.65e-05	0.000525	CcSEcCtD
Fulvestrant—ESR1—Generic Transcription Pathway—PGR—uterine cancer	4.63e-05	0.000769	CbGpPWpGaD
Fulvestrant—Rash—Epirubicin—uterine cancer	4.63e-05	0.000523	CcSEcCtD
Fulvestrant—Dermatitis—Epirubicin—uterine cancer	4.63e-05	0.000523	CcSEcCtD
Fulvestrant—Headache—Epirubicin—uterine cancer	4.6e-05	0.00052	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—DCN—uterine cancer	4.56e-05	0.000756	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—SMAD3—uterine cancer	4.55e-05	0.000755	CbGpPWpGaD
Fulvestrant—Dizziness—Doxorubicin—uterine cancer	4.49e-05	0.000508	CcSEcCtD
Fulvestrant—ESR1—Gene Expression—SUZ12—uterine cancer	4.48e-05	0.000744	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—ESR2—uterine cancer	4.47e-05	0.000743	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—PGR—uterine cancer	4.42e-05	0.000734	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—ERBB2—uterine cancer	4.39e-05	0.000729	CbGpPWpGaD
Fulvestrant—Nausea—Epirubicin—uterine cancer	4.36e-05	0.000493	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	4.36e-05	0.000724	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	4.35e-05	0.000722	CbGpPWpGaD
Fulvestrant—Vomiting—Doxorubicin—uterine cancer	4.32e-05	0.000488	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—STK11—uterine cancer	4.32e-05	0.000717	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CYP19A1—uterine cancer	4.32e-05	0.000717	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—HRAS—uterine cancer	4.3e-05	0.000714	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CYP11A1—uterine cancer	4.29e-05	0.000713	CbGpPWpGaD
Fulvestrant—Rash—Doxorubicin—uterine cancer	4.29e-05	0.000484	CcSEcCtD
Fulvestrant—Dermatitis—Doxorubicin—uterine cancer	4.28e-05	0.000484	CcSEcCtD
Fulvestrant—Headache—Doxorubicin—uterine cancer	4.26e-05	0.000481	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	4.22e-05	0.0007	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—EZH2—uterine cancer	4.2e-05	0.000698	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—AKT1—uterine cancer	4.1e-05	0.000681	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—ESR2—uterine cancer	4.08e-05	0.000677	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—CDKN1B—uterine cancer	4.06e-05	0.000675	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—MTHFR—uterine cancer	4.06e-05	0.000674	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.06e-05	0.000673	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—AKR1C3—uterine cancer	4.05e-05	0.000673	CbGpPWpGaD
Fulvestrant—Nausea—Doxorubicin—uterine cancer	4.04e-05	0.000456	CcSEcCtD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.87e-05	0.000642	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CTNNB1—uterine cancer	3.86e-05	0.000641	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	3.82e-05	0.000634	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—AKT1—uterine cancer	3.79e-05	0.00063	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—PTEN—uterine cancer	3.76e-05	0.000625	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—PTEN—uterine cancer	3.74e-05	0.000621	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—ESR1—uterine cancer	3.71e-05	0.000616	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	3.66e-05	0.000607	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—CDKN2B—uterine cancer	3.64e-05	0.000604	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	3.59e-05	0.000596	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—EP300—uterine cancer	3.59e-05	0.000596	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.58e-05	0.000594	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—uterine cancer	3.57e-05	0.000592	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	3.56e-05	0.000591	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	3.54e-05	0.000588	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	3.4e-05	0.000564	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	3.39e-05	0.000562	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	3.35e-05	0.000556	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—NRAS—uterine cancer	3.34e-05	0.000554	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—SMAD3—uterine cancer	3.32e-05	0.000552	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—CDKN2B—uterine cancer	3.32e-05	0.000551	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—MTHFR—uterine cancer	3.25e-05	0.000539	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	3.2e-05	0.000531	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—CDKN2B—uterine cancer	3.17e-05	0.000526	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—STK11—uterine cancer	3.16e-05	0.000524	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CYP19A1—uterine cancer	3.16e-05	0.000524	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	3.12e-05	0.000518	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—SMAD3—uterine cancer	3.03e-05	0.000503	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	2.97e-05	0.000494	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.96e-05	0.000492	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—SMAD3—uterine cancer	2.89e-05	0.000481	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—KRAS—uterine cancer	2.89e-05	0.00048	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—KRAS—uterine cancer	2.87e-05	0.000477	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.86e-05	0.000475	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—AKR1B10—uterine cancer	2.83e-05	0.00047	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.83e-05	0.000469	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	2.82e-05	0.000467	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—ESR1—uterine cancer	2.71e-05	0.00045	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	2.64e-05	0.000439	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—PIK3CA—uterine cancer	2.64e-05	0.000438	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	2.61e-05	0.000433	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—TP53—uterine cancer	2.57e-05	0.000426	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—HRAS—uterine cancer	2.44e-05	0.000405	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	2.39e-05	0.000397	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—MTHFR—uterine cancer	2.37e-05	0.000394	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—ESR1—uterine cancer	2.36e-05	0.000392	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—RNF43—uterine cancer	2.35e-05	0.00039	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PTEN—uterine cancer	2.26e-05	0.000375	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PGR—uterine cancer	2.23e-05	0.00037	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	2.2e-05	0.000365	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—AKT1—uterine cancer	2.17e-05	0.00036	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—AKT1—uterine cancer	2.16e-05	0.000358	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—EP300—uterine cancer	2.16e-05	0.000358	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—INHBA—uterine cancer	2.15e-05	0.000356	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	2.13e-05	0.000353	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—EZH2—uterine cancer	2.12e-05	0.000352	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.09e-05	0.000347	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—ESR2—uterine cancer	1.96e-05	0.000326	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—AKR1C1—uterine cancer	1.93e-05	0.000321	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PTEN—uterine cancer	1.81e-05	0.0003	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.8e-05	0.000298	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—EP300—uterine cancer	1.72e-05	0.000286	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—CDKN2B—uterine cancer	1.6e-05	0.000265	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PIK3CA—uterine cancer	1.59e-05	0.000265	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—AKR1C3—uterine cancer	1.49e-05	0.000247	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—SMAD3—uterine cancer	1.46e-05	0.000242	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PGR—uterine cancer	1.45e-05	0.000241	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.42e-05	0.000236	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.42e-05	0.000236	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—YWHAE—uterine cancer	1.38e-05	0.00023	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—AKT1—uterine cancer	1.34e-05	0.000222	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FBXW7—uterine cancer	1.33e-05	0.00022	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PTEN—uterine cancer	1.32e-05	0.000219	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—AKT1—uterine cancer	1.3e-05	0.000216	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PIK3CA—uterine cancer	1.27e-05	0.000212	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—EP300—uterine cancer	1.26e-05	0.000209	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—STK11—uterine cancer	1.16e-05	0.000193	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SOCS3—uterine cancer	1.09e-05	0.00018	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—AKT1—uterine cancer	1.04e-05	0.000173	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CDKN2B—uterine cancer	1.04e-05	0.000173	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—STAR—uterine cancer	1.03e-05	0.00017	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—AKR1B1—uterine cancer	1.03e-05	0.00017	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IGF1R—uterine cancer	1.01e-05	0.000168	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—AKT1—uterine cancer	9.78e-06	0.000162	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SMAD3—uterine cancer	9.49e-06	0.000158	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PIK3CA—uterine cancer	9.31e-06	0.000155	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FGFR2—uterine cancer	9.05e-06	0.00015	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—AKT1—uterine cancer	8.52e-06	0.000141	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—POLD1—uterine cancer	8.06e-06	0.000134	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—AKT1—uterine cancer	7.61e-06	0.000126	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—AKR1C1—uterine cancer	7.54e-06	0.000125	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCL2—uterine cancer	6.82e-06	0.000113	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—RRM2—uterine cancer	6.72e-06	0.000112	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—DCN—uterine cancer	6.52e-06	0.000108	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CYP11A1—uterine cancer	6.14e-06	0.000102	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—AKR1C3—uterine cancer	5.8e-06	9.63e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—ERBB2—uterine cancer	5.68e-06	9.44e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CXCL8—uterine cancer	5.39e-06	8.95e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CDKN1B—uterine cancer	5.26e-06	8.74e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CTNNB1—uterine cancer	4.97e-06	8.26e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PTEN—uterine cancer	4.85e-06	8.05e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—EP300—uterine cancer	4.62e-06	7.67e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—STK11—uterine cancer	4.52e-06	7.5e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CYP19A1—uterine cancer	4.52e-06	7.5e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—VEGFA—uterine cancer	4.38e-06	7.27e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NRAS—uterine cancer	4.32e-06	7.18e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—AKT1—uterine cancer	4.3e-06	7.13e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KRAS—uterine cancer	3.72e-06	6.18e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PIK3CA—uterine cancer	3.42e-06	5.68e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—MTHFR—uterine cancer	3.4e-06	5.64e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TP53—uterine cancer	3.31e-06	5.49e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HRAS—uterine cancer	3.16e-06	5.25e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—AKT1—uterine cancer	2.79e-06	4.64e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PTEN—uterine cancer	1.89e-06	3.14e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—EP300—uterine cancer	1.8e-06	2.99e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.33e-06	2.21e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—AKT1—uterine cancer	1.09e-06	1.81e-05	CbGpPWpGaD
